Compare
Addentax Group Corp. vs Iveda Solutions, Inc. vs Asiafin Holdings Corp. vs BioScience Health Innovations, Inc.
| Latest fiscal year | Addentax Group Corp. ATXG | Iveda Solutions, Inc. IVDA | Asiafin Holdings Corp. ASFH | BioScience Health Innovations, Inc. BHIC |
|---|---|---|---|---|
| Year ended | 2026-03-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $5.37M | $5.28M | $5.13M | $5.69M |
| Revenue growth (YoY) | +28.5% | -12.3% | +51.6% | +208.3% |
| Gross margin | 14.1% | 24.1% | 37.1% | 57.0% |
| Operating margin | -28.5% | -61.1% | 0.8% | 12.6% |
| Net margin | -83.2% | -60.6% | -1.7% | 11.3% |
| Net income | -$4.47M | -$3.20M | -$85.3K | $642.1K |
| EPS (Diluted) | -$6.27 | -$0.88 | $0.00 | $0.06 |
| Operating cash flow | -$603.6K | -$2.03M | $503.9K | $172.2K |
| Free cash flow | -$784.5K | n/a | $394.6K | n/a |
| Cash & equivalents | $574.3K | $5.16M | $1.75M | $661.9K |
| Total assets | $29.25M | $6.43M | $4.75M | $1.71M |
| Total liabilities | $7.57M | n/a | $2.19M | $229.9K |
| Shareholders' equity | $21.80M | $4.78M | $2.57M | $1.48M |
| Return on year-end equity | -20.5% | -66.9% | -3.3% | 43.5% |
| Shares outstanding | 781.3K | 5.88M | 81.92M | 10.98M |
Revenue, most recent five fiscal years
| Fiscal year | Addentax Group Corp. | Iveda Solutions, Inc. | Asiafin Holdings Corp. | BioScience Health Innovations, Inc. |
|---|---|---|---|---|
| Latest | $5.37M Ended 2026-03-31 | $5.28M Ended 2025-12-31 | $5.13M Ended 2025-12-31 | $5.69M Ended 2025-12-31 |
| 1 year earlier | $4.18M Ended 2025-03-31 | $6.02M Ended 2024-12-31 | $3.38M Ended 2024-12-31 | $1.84M Ended 2024-12-31 |
| 2 years earlier | $5.15M Ended 2024-03-31 | $6.50M Ended 2023-12-31 | $3.11M Ended 2023-12-31 | $597.6K Ended 2023-12-31 |
| 3 years earlier | $7.94M Ended 2023-03-31 | $4.47M Ended 2022-12-31 | n/a | $69.3K Ended 2022-12-31 |
| 4 years earlier | $12.69M Ended 2022-03-31 | $1.92M Ended 2021-12-31 | n/a | n/a |